[go: up one dir, main page]

PE20231425A1 - Composiciones farmaceuticas de pralsetinib - Google Patents

Composiciones farmaceuticas de pralsetinib

Info

Publication number
PE20231425A1
PE20231425A1 PE2022002769A PE2022002769A PE20231425A1 PE 20231425 A1 PE20231425 A1 PE 20231425A1 PE 2022002769 A PE2022002769 A PE 2022002769A PE 2022002769 A PE2022002769 A PE 2022002769A PE 20231425 A1 PE20231425 A1 PE 20231425A1
Authority
PE
Peru
Prior art keywords
pralsetinib
solubble
pharmaceutically acceptable
water
pharmaceutical compositions
Prior art date
Application number
PE2022002769A
Other languages
English (en)
Inventor
Joshua Waetzig
Gordon D Wilkie
Debra L Mazaik
Csanad M Varga
Lia Rogal
Lauren Maceachern
Kimberly Jean Miller
Shellie Rigby-Singleton
Ian A Barker
Robert J Harris
Aimee J Spenceley
Dipak Gordhan
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of PE20231425A1 publication Critical patent/PE20231425A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA DISPERSION SOLIDA AMORFA QUE COMPRENDE PRALSETINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE ESTE, Y UN POLIMERO HIDROFILICO FARMACEUTICAMENTE ACEPTABLE TAL COMO HIDROXIPROPILMETILCELULOSA, QUE ESTAN EN UNA PROPORCION EN PESO DE 1:1; B) UN PAR EFERVESCENTE QUE COMPRENDE UN ACIDO SOLUBLE EN AGUA TAL COMO ACIDO CITRICO Y UNA BASE SOLUBLE EN AGUA TAL COMO BICARBONATO DE SODIO; C) UN ANTIHUMECTANTE QUE ES ALMIDON PREGELATINIZADO; Y D) UN DILUYENTE QUE ES UNA CELULOSA MICROCRISTALINA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE CANCER DE PULMON DE CELULAS NO PEQUENAS (NSCLC).
PE2022002769A 2020-05-29 2021-05-28 Composiciones farmaceuticas de pralsetinib PE20231425A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063032030P 2020-05-29 2020-05-29
PCT/US2021/034811 WO2021243186A1 (en) 2020-05-29 2021-05-28 Pralsetinib pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PE20231425A1 true PE20231425A1 (es) 2023-09-13

Family

ID=76641805

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002769A PE20231425A1 (es) 2020-05-29 2021-05-28 Composiciones farmaceuticas de pralsetinib

Country Status (15)

Country Link
US (1) US20230203009A1 (es)
EP (1) EP4157230A1 (es)
JP (1) JP2023501757A (es)
KR (1) KR20230017229A (es)
CN (1) CN116133646A (es)
AU (1) AU2021281283A1 (es)
BR (1) BR112022024374A2 (es)
CA (1) CA3184648A1 (es)
CL (1) CL2022003353A1 (es)
CR (1) CR20220666A (es)
IL (1) IL298525A (es)
MX (1) MX2022015022A (es)
PE (1) PE20231425A1 (es)
TW (1) TW202210079A (es)
WO (1) WO2021243186A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195471A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
TW202136240A (zh) 2019-12-19 2021-10-01 美商亞文納營運公司 用於靶向降解雄激素受體之化合物及方法
WO2024209391A1 (en) * 2023-04-06 2024-10-10 Olon S.P.A. Process for preparing pralsetinib, and intermediates thereof in crystalline form

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009003136A1 (en) * 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
CA2871540A1 (en) * 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
EP4331585A3 (en) * 2015-11-02 2024-05-15 Blueprint Medicines Corporation Inhibitors of ret
CN110891573A (zh) * 2017-05-15 2020-03-17 缆图药品公司 Ret抑制剂和mtorc1抑制剂的组合及其用于治疗由异常ret活性介导的癌症的用途

Also Published As

Publication number Publication date
CN116133646A (zh) 2023-05-16
IL298525A (en) 2023-01-01
WO2021243186A1 (en) 2021-12-02
JP2023501757A (ja) 2023-01-18
KR20230017229A (ko) 2023-02-03
MX2022015022A (es) 2023-03-08
CR20220666A (es) 2023-05-05
CL2022003353A1 (es) 2023-07-14
BR112022024374A2 (pt) 2023-05-02
US20230203009A1 (en) 2023-06-29
AU2021281283A1 (en) 2022-12-15
TW202210079A (zh) 2022-03-16
EP4157230A1 (en) 2023-04-05
CA3184648A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
PE20231425A1 (es) Composiciones farmaceuticas de pralsetinib
MX2023000798A (es) Peptidos funcionalizados como agentes antivirales.
PE20230466A1 (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
NI201200172A (es) Activadores de guanilato ciclasa soluble
MXPA03002022A (es) Conjugados de inhibidor de neuraminidas multivalentes.
PE20211657A1 (es) Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
UA114351C2 (uk) Поліциклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування
MX2009011554A (es) Preparacion solida estable conteniendo un derivado de 4,5-epoximorfinano.
DK1898876T3 (da) Mucoadhæsive xyloglucanholdige fprmuleringer anvendelige i medicinske anordninger og i farmaceutiske former
WO2005028479A3 (en) Hiv replication inhibiting purine derivatives
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
WO2008132138A9 (en) AMINOPYRIMIDINE DERIVATIVES DISUBSTITUTED IN 4 AND 6
ECSP066327A (es) Composición de fexofenadina y proceso para prepararla
PE20120023A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
NO20092542L (no) Antibakterielle kinolin-derivater
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
NO20062082L (no) Pellets inneholdende venlafaksinhydroklorid
YU75403A (sh) Vodeni amfotericin b preparat
CY1111188T1 (el) Αντιβακτηριακα παραγωγα κινολινης
MX2022013298A (es) Conjugados de anticuerpos de farmacos.
PE20061390A1 (es) Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas
MX2009007040A (es) Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular.
SA523442503B1 (ar) مشتقات سبيروبيبريدينيل مستبدل بأريل غير متجانس واستخدامات صيدلانية لها
AU2018263059A1 (en) Compositions and treatment procedures for the treatment of pathogenic infections